Advertisement

Schmerztherapie und Symptomkontrolle in der Palliativmedizin

  • E. Klaschik
Chapter

Zusammenfassung

Wir verfügen über keine in Deutschland erhobenen Daten bezüglich der Häufigkeit (Inzidenz und Prävalenz) tumorbedingter Schmerzen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ahmedzai S (1993) Palliation of respiratory symptoms. In: Doyle D, Hanks GWC, Macdonald N (eds) Oxford textbook of palliative medicine; Oxford UnivPress, Oxford New York, S 349-378 Google Scholar
  2. 2.
    Ajemian I (1991) Palliative management of dyspnea. J Palliat Care 7/ 3: 44–45Google Scholar
  3. 3.
    Allan SG (1993) Nausea and vomiting. In: Doyle D, Hanks GWC, Macdonald N (eds) Oxford textbook of palliative medicine; Oxford UnivPress,Oxford New York, pp 282–290Google Scholar
  4. 4.
    American Pain Society (1989) Principles of analgesic use in the treatment of acute pain and chronic cancer pain. A concise guide to medical practice, 2nd edn. American Pain Society, Skokie/ILGoogle Scholar
  5. 5.
    Back IN (1992) Terminal restlessness in patients with advanced malignant disease. Palliat Med 6: 293–298CrossRefGoogle Scholar
  6. 6.
    Banning A, Sjogren P (1990) Cerebral effects of long-term oral opioid in cancer patiens measured by continuous reaction time Th. Clin J Pain 6: 91–95Google Scholar
  7. 7.
    Boas RA, Hoolford NHG, Villiger JW (1985) Clinical pharmacology of opiate analgesia. Adv Pain Res Ther 9: 695–708Google Scholar
  8. 8.
    Bonica JJ, Loeser JD, Chapmann CR, Fordyce WE (1990) The management of pain Lea Febiger, Philadelphia LondonGoogle Scholar
  9. 9.
    Bozzetti F et al. (1996) Guidelines on artificial nutrition versus hydration in terminal cancer patients. Nutrition 12 /3: 163–167PubMedCrossRefGoogle Scholar
  10. 10.
    Bruera E, Brenneis C, Paterson AH, MacDonald RM (1989) Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 4: 3PubMedCrossRefGoogle Scholar
  11. 11.
    Bruera E, Chadwich S, Brenneis C, Hanson J, MacDonald RM (1987) Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Report 76: 17Google Scholar
  12. 12.
    Bullingham R, McQuay H, Porter E, Weir L (1982) Sublingual buprenorphine used postoperatively: to hour plasma drug concentration analysis. Br J Clin Pharmacol 13: 665PubMedCrossRefGoogle Scholar
  13. 13.
    Campbell JN (1996) Pain 1996 - An updated review. IASP Press, SeattleGoogle Scholar
  14. 14.
    Cherny NI (1996) The medical treatment of pain in the terminal stages of cancer and other illnesses In: Campbell JN (ed) Pain 1996 - An updated review. IASP Press, Seattle, pp 469–484Google Scholar
  15. 15.
    Cherny NI, Portenoy RK, Raber M, Zenz M (1994) Medikamentöse Therapie von Tumorschmerzen, Teil I: Eigenschaften von Nichtopioiden und Opioiden. Der Schmerz 8: 195–209Google Scholar
  16. 16.
    Cherny NI, Portenoy RK, Raber M, Zenz M (1994) Medikamentöse Therapie von Tumorschmerzen, Teil II: Anwendung von Opioiden. Der Schmerz 9: 3–19Google Scholar
  17. 17.
    Cherny NI, Portenoy RK, Raber M, Zenz M (1995) Medikamentöse Therapie von Tumorschmerzen, Teil III: Adjuvanzien. Der Schmerz 9:55–69Google Scholar
  18. 18.
    Comroe JH, Forster RE, Dubois AB, Briscoe WA, Carlsen E (1968) Die Lunge. Schattauer, StuttgartGoogle Scholar
  19. 19.
    Cools HJM, Berkhout AMM, De Bock GH (1996) Subcutaneous morphine infusion by syringe driver for terminally ill patients. Age Ageing 25: 206–208PubMedCrossRefGoogle Scholar
  20. 20.
    Coyle N, Adelhardt J, Foley KM, Portenoy RN (1990) Character of terminal illness in the advanced cancer patient. J Pain Symptom Manage 5: 83PubMedCrossRefGoogle Scholar
  21. 21.
    Coyle H, Ingham J (1996) Pain management in the imminently dying–Goals of care, ethical issues, and the role of sedation: An illustrative case, In: Campbell JN (ed) Pain 1996–An updated review. IASP Press, Seattle, pp 567–570Google Scholar
  22. 22.
    Dejgard A, Petersen P, Kastrup J (1988) Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet I: 9–11Google Scholar
  23. 23.
    Devulder J, Ghys L, Dhondt W, Rolly G (1994) Spinal analgesia in terminal care: Risk versus benefit J Pain Symptom Manage 9/2: 75–81Google Scholar
  24. 24.
    Donner B, Strumpf M, Dertwinkel R, Zenz M (1997) Neue Alternative in der Tumortherapie. Richtige Anwendung von Fentanyl TTS entscheidend. Dtsch Ärztebl 94/10: A 598–599Google Scholar
  25. 25.
    Drechsler S, Bauer R (1995) 5-HT-3-Rezeptorantagonisten. Der Weg zum therapeutischen Fortschritt in der supportiven Tumortherapie Arzneimitteltherapie 8: 224-235Google Scholar
  26. 26.
    Ellershaw JE, Sutcliffe JM, Saunders CM (1995) Dehydration and the dying patient J Pain Symptom Manage 10/3: 192–197Google Scholar
  27. 27.
    Fainsinger R, Miller MJ, Bruera E (1991) Symptom control during the last week of life on a palliative care unit. J Palliat Care 7 /1: 5–11Google Scholar
  28. 28.
    Fainsinger RL, Spachynski K, Hanson J, Bruera E (1994) Symptom-control in terminally ill patients with malignant bowel obstruction (MB O) J Pain Symptom Manage 9/1: 12–18Google Scholar
  29. 29.
    Fainsinger RL, Bruera E (1994) The management of dehydration in terminally ill patients. Palliat Care 10: 55-59Google Scholar
  30. 30.
    Farncombe M, Chater S (1993) Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease J Pain Symptom Manage 8/4: 221–225Google Scholar
  31. 31.
    Foley KM (1989) Controversies in cancer pain: medical perspective. Cancer 63: 2257Google Scholar
  32. 32.
    Foley KM, Inturrisi CE (1987) Analgesic drug therapy in cancer pain: Principles and practice. Med Clin North Am 71: 107Google Scholar
  33. • Foley KM (1985) The treatment of cancer pain. N Engl J Med 313: 84Google Scholar
  34. 34.
    Foley KM (1993) Opioid analgesics in clinical pain management. In: Herz A (ed) Opioids. Handbook of experimental pharmacology, vol 1o4/II. Springer, Berlin Heidelberg New York Tokio, pp 697-743Google Scholar
  35. 35.
    Foley KM, Inturrisi CE (1989) Pharmacological approaches to cancer pain. In: Foley KM, Payne RM (eds) Current therapy of pain. Decker, Toronto, pp 303–331Google Scholar
  36. 36.
    Forman B, Portenoy RK,Yanagihara RH, Hunt WC, Kush R, Shepard K (1992) Elderly cancer patients with pain: response to oral morphine (MS) dose, pain and toxicity. J Am Geriatr Soc 40/10: SA 26Google Scholar
  37. 37.
    Freynhagen R, Zenz M, Strumpf M (1994) WHO Stufe II–Klinische Realität oder didaktisches Instrument. Der Schmerz 8: 210–215Google Scholar
  38. 38.
    Glare PA, Walsh TD (1993) Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol 11: 973–978PubMedGoogle Scholar
  39. 39.
    Goh CR (1996) Routes of opioid administration: The role of sublingual/buccal, transdermal, and parenteral infusion therapy In: Campbell JN (ed) Pain 1996 - An updated review. IASP Press, SeattleGoogle Scholar
  40. 40.
    Gordon N (1976) Reaction-times of methadone treated ex-heroin addicts. Psychopharmacologia 16: 337–44Google Scholar
  41. 41.
    Gorman DJ (1991) Opioid analgesics in the management of pain in patients with cancer: An update. Palliat Med 5: 277–294Google Scholar
  42. 42.
    Grond S, Zech D, Schug SA, Lynch J, Lehmann KA (1991) Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 6 /7: 411–412PubMedCrossRefGoogle Scholar
  43. 43.
    Grond S, Zech D (1992) Aktuelle Strategien in der Behandlung von Tumorschmerzen. Med Klinik 87 /4: 198–206Google Scholar
  44. 44.
    Grond S, Zech D, Meuser T, Radbruch L, Kasper M, Lehmann KA (1992) Prävalenz und Charakteristik neuropathischer Schmerzen bei malignen Erkrankungen. Der Schmerz 6: 99–104PubMedCrossRefGoogle Scholar
  45. 45.
    Grond S, Zech D, Dahlmann H, Schug SA, Stobbe B, Lehmann KA (1990) Überweisungsgrund: „therapieresistente“ Tumorschmerzen. Der Schmerz 4: 193–200PubMedCrossRefGoogle Scholar
  46. 46.
    Hanks GW, Justins DM (1992) Cancer pain: management. Lancet 39: 1031–1036CrossRefGoogle Scholar
  47. 47.
    Hanks GW, Twycross RG, Lloyd JW (1981) Unexpected complication of successful nerve block Anaesthesia 36: 37-39Google Scholar
  48. 48.
    Hanks GW (1996) Principles of Systemic Opioid Pharmacotherapy In: Campbell JN (ed) Pain 1996 - An Updated Review. IASP Press, SeattleGoogle Scholar
  49. 49.
    Hasselstrom J, Eriksson LS, Persson A (1990) Morphine metabolism in patients with liver cirrhosis. Br J Clin Pharmacol 29: 289PubMedCrossRefGoogle Scholar
  50. 50.
    Heyse-Moore LH, Poss V, Mullee MA (1991) How much of a problem is dyspnoea in advanced cancer? Palliat Med 5: 20–26CrossRefGoogle Scholar
  51. 51.
    Hildebrandt J (1994) Therapie chronischer Schmerzen. Jungjohann Verlagsges, NeckarsulmGoogle Scholar
  52. 52.
    Hogan Q, Haddox JD, Abram S, Weissmann D, Taylor ML, Janjan N (1991) Epidural opiates and local anesthetics for the management of cancer pain. Pain 46: 271–279PubMedCrossRefGoogle Scholar
  53. 53.
    Jage J (1995) Medikamente gegen Krebsschmerzen. Chapman Hall, London WeinheimGoogle Scholar
  54. 54.
    Jurna I, Baldauf J (1993) Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie. Der Schmerz 7: 314Google Scholar
  55. 55.
    Kalso E, Vainio A (1990) Morphine and oxycodone in the management of cancer pain. Clin Pharmacol Ther 47: 639–646PubMedCrossRefGoogle Scholar
  56. 56.
    Karavelis A, Foroglou G, Selviaridis P, Fountzilas G (1996) Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. Neurosurgery 39: 57–62PubMedCrossRefGoogle Scholar
  57. 57.
    Kaufmann PN, Krevsky B, Malmud LS, Maurer AH, Sommers MB, Siegel JA, Fisher RS (1988) Role of opiate receptors in the regulation of colonic transit. Gastroenterology 94: 1351Google Scholar
  58. 58.
    Lehmann KA (1994) Der postoperative Schmerz. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  59. 59.
    Lehmann KA, Zech D (1993) Morphine-6-glucuronide, a pharmacologically active morphine metabolite. Eur J Pain 14: 28-35Google Scholar
  60. 60.
    Lema MJ (1993) Cancer pain management: An overview of current therapeutic regimens. Semin Anesth XII/2: 109–117Google Scholar
  61. 61.
    Leutner V (1990) Schlaf, Schlafstörungen, Schlafmittel. Editiones Roches, BaselGoogle Scholar
  62. 62.
    Lichter I (1994) Accelerated titration of morphine for rapid relief of cancer pain. NZ Med J 107:488–490Google Scholar
  63. 63.
    Lichter I (1993) Results of antiemetic management in terminal illness. J Palliat Care 9/2: 19–21Google Scholar
  64. 64.
    Lindena G, Müller S, Zenz T (1994) Opioidverschreibung durch niedergelassene Ärzte. Der Schmerz 8: 228–234Google Scholar
  65. 65.
    Lloyd JW, Barnard JDW, Glynn CJ (1976) Cryoanalgesia: a new approach to pain relief. Lancet II: 932–934Google Scholar
  66. 66.
    Loick G, Radbruch L, Petzke F, Lehmann KA (1996) Tumorschmerztherapie bei geriatrischen Patienten im Vergleich mit jüngeren Patienten. Der Schmerz 10 (Suppl 1): 58Google Scholar
  67. 67.
    Lombardo WK, Lombardo B, Goldstein A (1976) Cognitive functioning under moderate and low dosage methadone maintenance. Int J Addict 11: 389–401PubMedGoogle Scholar
  68. 68.
    Lynn AM, Slattery JT (1987) Morphine pharmacokinetics in early infancy. Anesthesiology 66: 136–139PubMedCrossRefGoogle Scholar
  69. 69.
    MacDonald FC, Gough KJ, Nicoll RAG, Dow RJ (1989) Psychomotor effects of ketorolac in comparison with buprenorphine and diclofenac Br J Pharmacol 27: 453-59Google Scholar
  70. 70.
    Maloney CM, Kesner RK, Klein G, Bockenstette J (1989) The rectal administration of MS contin: Clinical implications of use in end stage cancer. Am J Hospice Care 6/4: 34–35Google Scholar
  71. 71.
    Mc-Quay HJ, Carroll D, Faura CC, Gavagghan DJ, Hand CW, Moore RA (1990) Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48: 236CrossRefGoogle Scholar
  72. 72.
    Maydell R von, Voltz R (1996) Palliativmedizin. Deutsche Gesellschaft für PalliativmedizinGoogle Scholar
  73. 73.
    Melzack R, Mount BM, Gordon JM (1979) The Brompton mixture versus morphine solution given orally: effects on pain. Can Med Assoc J 120: 435–439Google Scholar
  74. 74.
    O’Brien T, Monroe B (1990) Twenty-four hours before and after death In: Saunders C (ed) Hospice and palliative care. Arnold, LondonGoogle Scholar
  75. 75.
    Patwardhan RV, Johnson RF, Hoyumpa A (1981) Normal metabolism of morphine in cirrhosis. Gastroenterology 81: 1006–1011PubMedGoogle Scholar
  76. 76.
    Payne R, Thomas J, Prithivi Raj P (1992) Pain due to cancer epidemiology and pharmacological approach In: Prithivi Raj, P (ed) Practical management of pain. Mosby Year Book, St. LouisGoogle Scholar
  77. 77.
    Portenoy RK (1992) Cancer pain: pathophysiology and syndromes. Lancet 339: 1026–1031Google Scholar
  78. 78.
    Portenoy RK (1996) Nontraditional analgesics in the management of cancer Pain In: Campbell JN (ed) Pain 1996 - An updated review. IASP Press, SeattleGoogle Scholar
  79. 79.
    Porter J, Jick H (1980) Addiction is rare in patients treated with narcotics (letter) N Engl J Med 302: 123PubMedGoogle Scholar
  80. 80.
    Poyhia R, Seppala T, Olkkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33: 617–621PubMedCrossRefGoogle Scholar
  81. 81.
    Raffa RB, Friderichs E, Reimann W et al. (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an „atypical“ opioid analgesic. J Pharmacol Exp Ther 260: 275–85PubMedGoogle Scholar
  82. 82.
    Regnard C (1987) Nausea and vomiting–a flow diagram. Palliat Med 1: 62–63CrossRefGoogle Scholar
  83. 83.
    Regnard C, Hockley J (1995) Flow diagrams in advanced cancer and other diseases. Edward Arnold, London Boston Melbourne AucklandGoogle Scholar
  84. 84.
    Saarialho-Kere U, Mattila MJ, Paloheimo M, Seppälä T (1987) Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur J Clin Pharmacol 33: 139–46Google Scholar
  85. 85.
    Samuelsson H, Malmberg F, Eriksson M, Hedner T (1995) Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience J Pain Symptom Manage 10 /2: 105–112Google Scholar
  86. 86.
    Smith MT, Watt JA (1990) Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Life Sci 47: 579PubMedCrossRefGoogle Scholar
  87. 87.
    Schäle-Hein K (1989) Palliative Strahlenbehandlung In: Hankemeier U, Bowdler J, Zech D (ed) Tumorschmerztherapie. Springer, Berlin Heidelberg New York Tokio, pp 102–123Google Scholar
  88. 88.
    Schug SA, Merry AF, Acland RH (1991) Treatment principles for the use of opioids in pain of nonmalignant origin. Drugs 42 /2: 228–239PubMedCrossRefGoogle Scholar
  89. 89.
    Schuster CR (1989) Does treatment of cancer pain with narcotics produce junkies? In: Hill CS, Fields WS (eds) Drug treatment of cancer pain in a drug-oriented society. Raven, New York (Advances in pain research and therapy, vol 11, p 1 )Google Scholar
  90. 90.
    Stein WM (1996) Cancer pain in the elderly. In: Ferrell BR, Ferrell BA (eds) Pain in the elderly. IASP Press, SeattleGoogle Scholar
  91. 91.
    Striebel HW, Wessel A, Rieger A (1993) Intranasales Fentanyl zur Therapie akuter Schmerzspitzen bei Karzinompatienten. Eine Pilotstudie. Der Schmerz 7: 174–177Google Scholar
  92. 92.
    Teuscher E (1979) Pharmazeutische Biologie - Alkaloide. Vieweg, BraunschweigCrossRefGoogle Scholar
  93. 93.
    Teuscher E (1987) Biogene Gifte - Isochinolin-Alkaloide. G. Fischer, StuttgartGoogle Scholar
  94. 94.
    Tigerstedt I, Sepponen J, Tammisto T, Turunen M (1977) Comparison of nefopam and pethidine in postoperative pain. Br J Anaesth 49: 1133–1138PubMedCrossRefGoogle Scholar
  95. 95.
    Twycross RG (1979) Effect of cocaine in the brompton cocktail. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG (eds) Advances in pain research and therapy, vol 3. Raven, New York, pp 927–932Google Scholar
  96. 96.
    Twycross R (1994) Pain relief in advanced cancer. Churchill Livingstone, EdinburghGoogle Scholar
  97. 97.
    Twycross R (1993) Symptom control: the problem areas. Palliat Med 7 (Suppl 1): 1–8Google Scholar
  98. 98.
    Twycross R, Lack SA (1984) Symptom control in far advanced cancer. Pain relief. Pitman, LondonGoogle Scholar
  99. 99.
    Vainio A, Tigerstedt I (1988) Opioid treatment for radiating cancer pain: oral administration vs epidural techniques. Acta Anaesth Scand 32: 179–85Google Scholar
  100. 100.
    Vainio A, 011ila J, Matikainen E, Rosenberg P, Kalso E (1995) Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346: 667–670Google Scholar
  101. 101.
    Ventafridda V, Ripamonti C, Bianchi M, Sbanotto A, De Conno F (1986) A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1: 203–207PubMedCrossRefGoogle Scholar
  102. 102.
    Walker VA, Hoskin PJ, Hanks GW, White ID (1988) Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Manage 3/3: 145–149Google Scholar
  103. 103.
    Walsh TD (1984) Opiates and respiratory function in advanced cancer In: Zimmermann M, Drings P, Wagner G (eds) Pain in cancer patients. Springer, Berlin Heidelberg New York Tokio, pp 115–117Google Scholar
  104. 104.
    Walsh TD (1990) Prevention of opioid side effects. J Pain Symptom Manage 5 /6: 362–367PubMedCrossRefGoogle Scholar
  105. 105.
    Warfield CA (1993) Guidelines for routine use of controlled-release oral morphine sulfate tablets. Semin Oncol 20/2 (Suppl 1) pp 36–47 io6.WHO (1996) Cancer pain relief, with a guide to opioid availability.World Health Organization, GenevaGoogle Scholar
  106. 107.
    WHO Expert Commitee Report (1990) Cancer pain relief and palliative care. Technical report service no. 804. World Health Organization, GenevaGoogle Scholar
  107. 108.
    Willweber-Strumpf A, Zenz M, Tryba M (1995) Leitlinien zur Therapie chronischer Schmerzen mit Opioiden. Anaesthesist 44: 719-723Google Scholar
  108. 109.
    WinkelmüllerW (1992) Neurostimulation: Einführung in die Thematik. Der Schmerz 6 (Suppl 1): 26Google Scholar
  109. 11o.
    Yaksh TL (1996) Intrathecal and epidural opiates: A review. In: Campbell JN (ed) Pain 1996–An updated review. IASP Press, Seattle, pp 381–393Google Scholar
  110. 111.
    Zech D, Schug SA, Grond S (1992) Therapiekompendium Tumorschmerz und Symptomkontrolle. Perimed-Spitta, ErlangenGoogle Scholar
  111. 112.
    Zech D, Grond S, Lehmann KA (1995) Transdermales Fentanyl zur Behandlung von Tumorschmerzen. Dtsch Ärztebl 92: A 2554-2561Google Scholar
  112. 113.
    Zenz M (1995) Taschenbuch der Schmerztherapie. Wiss. Verlagsges., StuttgartGoogle Scholar
  113. 114.
    Zenz M, Jurna I (1993) Lehrbuch der Schmerztherapie Wissenschaftl. Verl., StuttgartGoogle Scholar
  114. 115.
    Zenz M (1993) Neues und Bewährtes in der medikamentösen Behandlung des chronischen Schmerzes. Der Schmerz (Suppl) 5: 52Google Scholar
  115. 116.
    Zenz M, Strumpf M, Tryba M (1992) Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 7: 69–77PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • E. Klaschik

There are no affiliations available

Personalised recommendations